NuCube Energy | $13,000,000 | (Feb 20, 2026)
Vizzia | $35,300,400 | (Feb 20, 2026)
PolyGone Systems Inc | $4,000,000 | (Feb 20, 2026)
Alpha-9 Oncology
United States
- Boston, Massachusetts
- 24/10/2024
- Series C
- $175,000,000
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
- Industry Biotechnology Research
- Website https://www.a9oncology.com/
- LinkedIn https://www.linkedin.com/company/a9oncology/
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
Eagle Wireless | $30,000,000 | (Feb 20, 2026)
Stacks | $23,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Adronite | $5,000,000 | (Feb 20, 2026)
Odynn | $9,500,000 | (Feb 20, 2026)
Ascent(US) | $45,000,000 | (Feb 20, 2026)
Ownwell | $50,000,000 | (Feb 20, 2026)
Badge | $17,100,000 | (Feb 20, 2026)